



NEOGEN
CHEMICALS LTD.

August 6, 2022

BSE Limited Department of Corporate Services Floor 25, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 Scrip Code No: 542665	National Stock Exchange of India Limited Listing Department, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Company Symbol: NEOGEN
--	---

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on Saturday, August 6, 2022.

With reference to the captioned subject and in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 (“Listing Regulations”), we wish to inform you that the Board of Directors of the Company had at its meeting held today i.e. Saturday, August 6, 2022, inter alia considered and approved the following:

1. Approval of Un-audited (Standalone & Consolidated) Financial Results of the Company for the quarter ended June 30, 2022, pursuant to Regulation 33 of the Listing Regulations along with the “Limited Review Report” thereon as provided by the Statutory Auditors of the Company, which has been duly reviewed and recommended by the Audit Committee and the same is enclosed herewith;
2. Approval of Directors’ Report with annexures, Management Discussion and Analysis Report, Business Responsibility Report and Corporate Governance Report for the financial year 2021-22 and Notice convening 33rd Annual General Meeting (AGM) of the Company;
3. The 33rd AGM of the Company will be held on Wednesday, September 28, 2022 at 5.00 p.m. through video conferencing and Other Audio-Visual Means (OAVM);
4. Record date/Cutoff Date is Tuesday, September 20, 2022 for deciding eligibility of members for remote e-voting and final dividend for the financial year 2021-22;
5. Register of Members and Share Transfer Register will remain closed from Wednesday, September 21, 2022 to Wednesday, September 28, 2022 (both days inclusive) for the purpose of ascertaining the eligible members who shall be entitled to receive the dividend, if approved by the members at the 33rd AGM of the Company; and
6. Pursuant to Regulation 32 of Listing Regulations, we enclose herewith Statement of Deviation/ Variation in utilization of funds (“Statement”) as at June 30, 2022, which has been duly reviewed by the Audit Committee.



Registered Office : 1002, Dev Corpora, Cadbury Junction,
Eastern Express Highway, Thane (W) 400 601, India.
CIN No. L24200MH1989PLC050919

E : sales@neogenchem.com
W : www.neogenchem.com

T : +91 22 2549 7300
F : +91 22 2549 7399



NEOGEN
CHEMICALS LTD.

The Board Meeting commenced at 7.00 p.m. and concluded at 8.45 p.m.

The Un-audited Financial Results and above information are also being uploaded on the Company's website at <https://neogenchem.com/financial-performance/>.

Kindly take the above information on your records.

Yours faithfully,
For **Neogen Chemicals Limited**



Unnati Kanani
Company Secretary & Compliance Officer
Membership No: ACS 35131

Encl.: 1) Un-audited Financial Results (Standalone & Consolidated) of the Company along with Limited Review Report for the quarter ended June 30, 2022.
2) Declaration pursuant to Regulation 32 of Listing Regulations



**Independent Auditors' Limited Review Report on Unaudited Standalone
Quarterly Results Of The Company**

Review report to
**The Board of Directors
Neogen Chemicals Limited**

We have reviewed the accompanying statement of unaudited financial results of **Neogen Chemicals Limited** ("the Company") for the quarter ended June 30, 2022 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations") as amended.

This statement is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 Interim Financial Reporting (Ind AS-34) as prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.


Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

UDIN:22039910AOMACA5539

For **JMT & Associates**

Chartered Accountants

FRN No. 104167W


JAYESH SHAH

Partner

Membership No. 039910




Mumbai, August 6, 2022



Statement of Standalone Unaudited Financial Results for the Quarter Ended June 30, 2022

(Rs. in Cr.)

Sr. No.	Particulars	Standalone			
		For the Quarter Ended			For the Year Ended
		30 June 2022	31 Mar 2022	30 June 2021	31 Mar 2022
		Unaudited	Audited	Unaudited	Audited
I	Income				
	(a) Revenue from operations	147.90	156.80	84.64	487.25
	(b) Other income	0.96	0.96	0.09	1.34
	Total Income	148.86	157.76	84.73	488.59
II	Expenses				
	(a) Cost of materials consumed	109.63	108.34	64.49	343.77
	(b) Changes in inventories of finished goods, work-in progress and stock-in-trade	(27.93)	(18.13)	(17.97)	(68.80)
	(c) Employee benefits expense	9.86	8.91	6.08	31.50
	(d) Finance costs	6.09	5.02	3.62	19.08
	(e) Depreciation and Amortization Expense	3.89	3.79	1.84	11.69
	(f) Other Expenses	31.69	31.06	16.42	94.19
	Total Expenses	133.23	138.99	74.48	431.43
III	Profit/(loss) before taxes (I-II)	15.63	18.77	10.25	57.16
IV	Income Tax				
	1. Current Tax	3.71	2.83	2.55	9.87
	2. Deferred Tax	0.80	0.27	0.32	2.57
V	Profit for the period (III-IV)	11.12	15.67	7.38	44.72
VI	Other comprehensive income				
	i) Items that will not be reclassified to profit or loss	(0.09)	(0.42)	0.01	(0.40)
	(ii) Income tax related to items that will not be reclassified to profit or loss	0.03	0.12	(0.01)	0.12
	Total Other comprehensive (expense)/ income, net of tax	(0.06)	(0.30)	0.00	(0.28)
VII	Total comprehensive income for the period (V + VI)	11.06	15.37	7.38	44.44
VIII	Paid up equity Share Capital (Face Value per share of Rs. 10/- each)	24.94	24.94	23.33	24.94
IX	Other Equity				414.38
X	Earnings Per Share Rs.				
	Basic & Diluted (*Not Annualized)	4.46*	5.50*	3.16*	18.74



For and on behalf of the Board of Directors of
Neogen Chemicals Limited

Dr. Harin Kanani
Managing Director
DIN : 05136947

Place : Thane , India
Date : 6th August, 2022



Notes :

1. The above unaudited financial results of the Company for the quarter ended June 30, 2022 have been prepared in accordance with the IND AS, as prescribed under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 and were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 06, 2022.
2. The Company had allotted 16,04,710 equity shares of a face value of Rs. 10 each on a preferential basis at an issue price of Rs. 1402.12 per equity share aggregating to Rs. 225 crores on 6th January, 2022. The details of utilization of the said proceeds raised by way of issue of Equity shares on preferential Issue basis are as follows:

(Rs. In crore)

Sr.no.	Particulars	Proposed Allocation of Fund	Utilized as on 30.06.2022*	Unutilized amount as at 30.06.2022
1	funding the long-term growth and expansion of its existing businesses;	225	209	16
2	financing capital expenditure & working capital requirements;			
3	pre-payment and / or repayment of working capital loans;			
4	General corporate purpose;			
5	Any other matters as may be permissible under applicable law(s).			
	Total Amount	225	209	16

*Funds utilised includes Rs. 7.3 crore on account of issue related expenses

3. Previous period / year's figures have been regrouped/rearranged wherever necessary to make them comparable.
4. The figures for the quarter ended 31st March, 2022 are balancing figures between the audited figures in respect of the full financial year and the published year to date figures for the nine-month period ended 31st December, 2021.
5. The company is in the business of manufacturing of specialty chemicals and accordingly has one reportable business segment.
6. For more details on results, visit investor relations section of the Company's website at www.neogenchem.com and financial result under corporates section of Stock Exchange's website at www.nseindia.com and www.bseindia.com.

Place : Thane , India
Date : 6th August ,2022



For and on behalf of the Board of Directors of
Neogen Chemicals Limited

Dr. Harin Kanani
Managing Director
DIN : 05136947




Independent Auditors' Limited Review Report on unaudited consolidated quarterly results of the Company

**TO THE BOARD OF DIRECTORS OF
NEOGEN CHEMICALS LIMITED**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **NEOGEN CHEMICALS LIMITED** ("the Parent") and its subsidiaries/Join Venture (the Parent and its subsidiaries and Joint Ventures together referred to as "the Group"), and its share of the **net profit** after tax of its associates and joint ventures for the quarter ended **June 30, 2022** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended June 30, 2022 under equity method for joint ventures, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. The Statement includes the results of the following entities:

List of Joint Venture

Dhara Finchem Industries (Registered Partnership Firm)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the branch auditors and other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We have reviewed the financial statements of Dhara Fine Chem Industries joint operations whose financial results of the entity included in the Group are accounted on equity method. In our opinion and according to the information and explanations given to us by the Management, the financial results of the Joint Venture are *not material* to the Group.


Our opinion on the statement is not modified in respect of the above matters.

UDIN : 22039910AOMAWG5718

For **JMT & Associates**

Chartered Accountants

FRN No. 104167W


JAYESH SHAH

Partner

Membership No. 039910



Mumbai, August 6, 2022



Statement of Consolidated Unaudited Financial Results for the Quarter ended June 30, 2022

(Rs. in Cr.)

Sr. No	Particulars	Consolidated			
		For the Quarter Ended			For the Year Ended
		30 June 2022	31 Mar 2022	30 June 2021	31 Mar 2022
		Unaudited	Audited	Unaudited	Audited
I	Income				
	(a) Revenue from operations	147.90	156.80	84.64	487.25
	(b) Other income	0.90	0.85	0.03	1.07
	Total Income	148.80	157.65	84.67	488.32
II	Expenses				
	(a) Cost of materials consumed	109.63	108.34	64.49	343.77
	(b) Changes in inventories of finished goods, work-in progress and stock-in-trade	(27.93)	(18.13)	(17.97)	(68.80)
	(c) Employee benefits expense	9.86	8.91	6.08	31.50
	(d) Finance costs	6.09	5.02	3.62	19.08
	(e) Depreciation and Amortization Expense	3.89	3.79	1.84	11.69
	(f) Other Expenses	31.69	31.06	16.42	94.19
	Total Expenses	133.23	138.99	74.48	431.43
III	Share of profit from Joint Venture	0.04	0.08	0.04	0.18
IV	Profit/(loss) before taxes (I - II + III)	15.61	18.74	10.23	57.07
V	Income Tax				
	1. Current Tax	3.71	2.83	2.55	9.87
	2. Deferred Tax	0.80	0.27	0.32	2.57
VI	Profit for the period (IV-V)	11.10	15.64	7.36	44.63
VII	Other comprehensive income				
	i) Items that will not be reclassified to profit or loss	(0.09)	(0.42)	0.01	(0.40)
	(ii) Income tax related to items that will not be reclassified to profit or loss	0.03	0.12	(0.01)	0.12
	Total Other comprehensive (expense)/ income, net of tax	(0.06)	(0.30)	0.00	(0.28)
VIII	Total comprehensive income for the period (VI+VII)	11.04	15.34	7.36	44.35
IX	Paid up equity Share Capital (Face Value per share of Rs. 10 each)	24.94	24.94	23.33	24.94
X	Other Equity				414.30
XI	Earning Per Equity Share Rs.				
	(a) Basic & Diluted (*Not Annualized)	4.45*	5.50*	3.15*	18.70

For and on behalf of Board of Directors of
Neogen Chemicals Ltd



Dr. Harin Kanani
Managing Director
DIN : 05136947

Place: Thane, India
Date : 6th August 2022



Notes :

1. The above unaudited financial results of the Company for the quarter ended June 30, 2022 have been prepared in accordance with the IND AS, as prescribed under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 and were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 06, 2022.
2. The Company had allotted 16,04,710 equity shares of a face value of Rs. 10 each on a preferential basis at an issue price of Rs. 1402.12 per equity share aggregating to Rs. 225 crores on 6th January, 2022. The details of utilization of the said proceeds raised by way of issue of Equity shares on preferential Issue basis are as follows:

(Rs. In crore)

Sr.no.	Particulars	Proposed Allocation of Fund	Utilized as on 30.06.2022*	Unutilized amount as at 30.06.2022
1	funding the long-term growth and expansion of its existing businesses;	225	209	16
2	financing capital expenditure & working capital requirements;			
3	pre-payment and / or repayment of working capital loans;			
4	General corporate purpose;			
5	Any other matters as may be permissible under applicable law(s).			
	Total Amount	225	209	16

*Funds utilised includes Rs. 7.3 crore on account of issue related expenses

3. Previous period / year's figures have been regrouped/rearranged wherever necessary to make them comparable.
4. The figures for the quarter ended 31st March, 2022 are balancing figures between the audited figures in respect of the full financial year and the published year to date figures for the nine-month period ended 31st December, 2021.
5. The company is in the business of manufacturing of specialty chemicals and accordingly has one reportable business segment.
6. For more details on results, visit investor relations section of the Company's website at www.neogenchem.com and financial result under corporates section of Stock Exchange's website at www.nseindia.com and www.bseindia.com.

Place : Thane , India
Date : 6th August ,2022



For and on behalf of the Board of Directors of
Neogen Chemicals Limited

Dr. Harin Kanani
Managing Director
DIN : 05136947



NEOGEN
CHEMICALS LTD.

August 6, 2022

BSE Limited Department of Corporate Services Floor 25, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 Scrip Code No: 542665	National Stock Exchange of India Limited Listing Department, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Company Symbol: NEOGEN
---	--

Dear Sir/Madam,

Sub: Disclosure under regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 ("Listing Regulations")

Ref.: SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019

Pursuant to Regulation 32 of Listing Regulations, we enclose herewith Statement of Deviation / Variation ("Statement") for the quarter ended June 30, 2022, duly reviewed by the Audit Committee at its meeting held on August 6, 2022.

We hereby confirm that there has been no deviation or variation in the use of proceeds of funds raised through issue of Equity Shares on preferential basis.

This intimation is also being uploaded on the Company's website at <https://neogenchem.com/announcements/>.

Kindly take the above on your record and disseminate the same for the information of investors.

Thanking you,
Yours faithfully,
For Neogen Chemicals Limited

Unnati Kanani
Company Secretary & Compliance Officer
Membership No: ACS 35131
Encl: A/a



Registered Office : 1002, Dev Corpora, Cadbury Junction,
Eastern Express Highway, Thane (W) 400 601, India.
CIN No. L24200MH1989PLC050919

E : sales@neogenchem.com
W : www.neogenchem.com

T : +91 22 2549 7300
F : +91 22 2549 7399



Quarterly Reporting for Preferential Issue of Equity Shares under Regulation 32 of Listing Regulation.

Statement of Deviation / Variation in utilisation of funds raised

Name of listed entity	Neogen Chemicals Limited
Mode of Fund Raising	Preferential Issue of Equity Shares
Date of Raising Funds	06-01-2022
Amount Raised (Rs. In crores)	225 crores
Report filed for Quarter ended	30-06-2022
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	Nil
Comments of the auditors, if any	Nil
Objects for which funds have been raised and where there has been a deviation, in the following table	See table below


(Amount in Crores)

Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised till 30.06.2022*	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
a) funding the long term growth and expansion of its existing businesses;	Not Applicable	225	Not Applicable	209	Nil	Nil
b) financing capital expenditure & working capital requirements;						
c) pre-payment and / or repayment of loans;						
d) General corporate purpose; and / or						
e) Any other matters as may be permissible under applicable law(s).						
		225		209		
Deviation or variation could mean:						

(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.

Name of Signatory		Ketan Vyas
Designation		Chief Financial Officer
Date		06-08-2022



*Funds Utilised includes Rs. 7.3 crore on account of issue related expenses